Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report

Journal of Medical Case Reports

Fred Kidaaga²  Paul Kioko Ngalyuka⁴  Philip Nakangombe³  Celia Nantume Mukulu¹  Safia AbdallahYussuf⁴  Nuru Kaddu Mgori⁴  Innocent Lule Segamwenge⁴ 

[1] Department of Radiology, Intermediate Hospital Oshakati, Oshakati, Namibia;Namibian Institute of Pathology, Khomas, Namibia;Department of Urology, Intermediate Hospital Oshakati, Oshakati, Namibia;Department of Internal Medicine, Intermediate Hospital Oshakati, Private Bag 5501, Oshakati, Namibia

关键词: Prostate cancer;    Osteolytic;    Metastases;    Bone;   

Others  :  1195179
DOI  :  10.1186/1752-1947-6-425

 received in 2012-09-21, accepted in 2012-10-31,  发布年份 2012

【 摘 要 】

Introduction

Prostate cancer is the second most common cancer in men and the fifth most common cancer worldwide. In the USA it is more common in African-American men than in Caucasian men. Prostate cancer frequently metastasizes to bone and the lesions appear osteoblastic on radiographs. Presentation with diffuse osteolytic bone lesions is rare. We describe an unusual presentation of metastatic prostate cancer with diffuse osteolytic bone lesions.

Case presentation

A 65-year-old Namibian man presented with anemia, thrombocytopenia and worsening back pains. In addition he had complaints of effort intolerance, palpitations, dysuria and mild symptoms of bladder outlet obstruction. On examination he was found to be anemic, had a swollen tender right shoulder joint and spine tenderness to percussion. On digital rectal examination he had asymmetrical enlargement of the prostate which felt nodular and hard with diffuse firmness in some parts. His prostate-specific antigen was greater than 100ng/mL and he had diffuse osteolytic lesions involving the right humerus, and all vertebral, femur and pelvic bones. His screen for multiple myeloma was negative and the prostate biopsy confirmed prostate cancer.

Conclusion

Prostate cancer rarely presents with diffuse osteolytic bone lesions and should be considered in the differential diagnosis when evaluating male patients with osteolytic bone lesions.

【 授权许可】

   
2012 Segamwenge et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Int Agency Res Canc 2010. http://globocan.iarc.fr webcite
• [2]Freddy S, Max P, Zvavahera C, Lara S, Nokuzola M, Henry W, et al.: Cancers. In Disease and Mortality in Sub-Saharan Africa. 2nd edition. Edited by Jamison DT, Feachem RG, Makgoba MW. Washington DC: World Bank; 2006.
• [3]Danley KL, Richardson JL, Bernstein L, Langholz B, Ross RK, et al.: Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States). Cancer Causes Control 1995, 6(6):492-498.
• [4]Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH, et al.: A typical metastases from prostate cancer: 10-year experience at a single institution. Am J Roentgenol 2012, 199(2):367-372.
• [5]Saad F, Clarke N, Colombel M: Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006, 49(3):429-440.
• [6]Rajendiran G, Green L, Chhabra G: A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. Int J Case Rep Image 2011, 2(9):16-20.
• [7]Migita T, Maeda K, Ogata N: A case of prostate cancer associated with osteolytic bone metastases. Hinyokika Kiyo 1999, 45(5):371-374.
• [8]Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ, et al.: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31(5):578-583.
• [9]Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ, et al.: Rapid (“Warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000, 6(3):1038-1045.
• [10]Tantivejkul K, Kalikin LM, Pienta KJ: Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004, 91(4):706-717.
• [11]Wang ZL, Wang XF: Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer. Zhonghua Nan Ke Xue 2005, 11(11):825-827.
• [12]Keller ET, Brown J: Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91(4):718-729.
• [13]Boyce BF, Xing L: Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007, 9(Suppl 1):S1. BioMed Central Full Text
• [14]Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL, et al.: Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001, 57(4):611-616.
• [15]Perlmutter MA, Lepor H: Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007, 9(Suppl 1):S3-S8.